{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Regorafenib",
    "query": {
      "condition": "Regorafenib"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 104,
    "total_pages": 11,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Regorafenib&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-27T05:35:41.984Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01187615",
      "title": "Determination of Safety, Efficacy, and Pharmacokinetics of \"Regorafenib\" Combined With Pemetrexed and Cisplatin in Patients With Nonsquamous Non-Small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Small Cell Lung Carcinoma"
      ],
      "interventions": [
        {
          "name": "Regorafenib (BAY73-4506) - sequential / Cisplatin / Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Regorafenib (BAY73-4506) - continuous / Cisplatin / Pemetrexed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2010-08",
      "completion_date": "2012-06",
      "has_results": false,
      "last_update_posted_date": "2014-07-08",
      "last_synced_at": "2026-06-27T05:35:41.984Z",
      "location_count": 4,
      "location_summary": "New Haven, Connecticut • Las Vegas, Nevada • New York, New York + 1 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01187615"
    },
    {
      "nct_id": "NCT05594147",
      "title": "An Observational Study, Called ROCURS, to Learn About COVID-19 Related Outcomes in People With Cancer Who Are Treated With Tyrosine Kinase Inhibitors (TKIs) Including Regorafenib or Sorafenib",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Malignant Solid Tumors",
        "Coronavirus Disease 2019 (COVID-19)",
        "SARS-CoV-2 Infection"
      ],
      "interventions": [
        {
          "name": "Non-TKIs",
          "type": "DRUG"
        },
        {
          "name": "Other TKIs",
          "type": "DRUG"
        },
        {
          "name": "Regorafenib (Stivarga, BAY73- 4506)",
          "type": "DRUG"
        },
        {
          "name": "Sorafenib (Nexavar, BAY43-9006)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4103,
      "start_date": "2022-10-31",
      "completion_date": "2023-04-21",
      "has_results": false,
      "last_update_posted_date": "2023-11-07",
      "last_synced_at": "2026-06-27T05:35:41.984Z",
      "location_count": 1,
      "location_summary": "Whippany, New Jersey",
      "locations": [
        {
          "city": "Whippany",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05594147"
    },
    {
      "nct_id": "NCT03347292",
      "title": "Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Carcinoma, Hepatocellular"
      ],
      "interventions": [
        {
          "name": "Regorafenib(Stivarga, BAY73-4506)",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 58,
      "start_date": "2018-06-18",
      "completion_date": "2022-09-06",
      "has_results": false,
      "last_update_posted_date": "2023-07-25",
      "last_synced_at": "2026-06-27T05:35:41.984Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Gainesville, Florida • Tampa, Florida + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03347292"
    },
    {
      "nct_id": "NCT02287727",
      "title": "Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rectal Adenocarcinoma",
        "Stage IIA Rectal Cancer",
        "Stage IIB Rectal Cancer",
        "Stage IIC Rectal Cancer",
        "Stage IIIA Rectal Cancer",
        "Stage IIIB Rectal Cancer"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Regorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2015-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2016-10-12",
      "last_synced_at": "2026-06-27T05:35:41.984Z",
      "location_count": 3,
      "location_summary": "Buffalo, New York • Rocherster, New York • Columbus, Ohio",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Rocherster",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02287727"
    },
    {
      "nct_id": "NCT02116894",
      "title": "Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "PF-03446962",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Regorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2014-08",
      "completion_date": "2016-05",
      "has_results": false,
      "last_update_posted_date": "2019-03-14",
      "last_synced_at": "2026-06-27T05:35:41.984Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02116894"
    },
    {
      "nct_id": "NCT02119676",
      "title": "Study of Ruxolitinib in Colorectal Cancer Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "CRC (Colorectal Cancer)"
      ],
      "interventions": [
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        },
        {
          "name": "Regorafenib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 396,
      "start_date": "2014-03",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2018-02-13",
      "last_synced_at": "2026-06-27T05:35:41.984Z",
      "location_count": 57,
      "location_summary": "Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 54 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02119676"
    },
    {
      "nct_id": "NCT02278783",
      "title": "Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Primary Peritoneal Cancer",
        "Fallopian Tube Cancer"
      ],
      "interventions": [
        {
          "name": "regorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 1,
      "start_date": "2015-03",
      "completion_date": "2017-01",
      "has_results": true,
      "last_update_posted_date": "2017-10-06",
      "last_synced_at": "2026-06-27T05:35:41.984Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02278783"
    },
    {
      "nct_id": "NCT03465722",
      "title": "(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "GIST"
      ],
      "interventions": [
        {
          "name": "avapritinib",
          "type": "DRUG"
        },
        {
          "name": "regorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Blueprint Medicines Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 476,
      "start_date": "2018-03-26",
      "completion_date": "2021-09-15",
      "has_results": true,
      "last_update_posted_date": "2022-10-06",
      "last_synced_at": "2026-06-27T05:35:41.984Z",
      "location_count": 30,
      "location_summary": "Phoenix, Arizona • Santa Monica, California • Aurora, Colorado + 26 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boulder",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03465722"
    },
    {
      "nct_id": "NCT02383433",
      "title": "Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Pancreatic Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Regorafenib",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2016-06-14",
      "completion_date": "2018-05-10",
      "has_results": true,
      "last_update_posted_date": "2023-10-23",
      "last_synced_at": "2026-06-27T05:35:41.984Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02383433"
    },
    {
      "nct_id": "NCT02098538",
      "title": "Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adenoid Cystic Carcinoma"
      ],
      "interventions": [
        {
          "name": "Regorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2014-03",
      "completion_date": "2024-11-07",
      "has_results": true,
      "last_update_posted_date": "2025-09-10",
      "last_synced_at": "2026-06-27T05:35:41.984Z",
      "location_count": 5,
      "location_summary": "Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 2 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Rockville Centre",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02098538"
    }
  ]
}